期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同剂量辛伐他汀治疗早期糖尿病肾病的疗效与安全性观察 被引量：8

下载PDF
导出
摘要 目的观察比较辛伐他汀40 mg/d与20 mg/d对早期糖尿病肾病患者的疗效与安全性。方法将确诊为早期糖尿病肾病的患者138例随机分成2组,每组69例。A组给予辛伐他汀40 mg/d,B组给予辛伐他汀20 mg/d。治疗前及治疗后4周、12周检查血肌酐(Scr)、尿白蛋白排泄率(UAER)、丙氨酸氨基转移酶(ALT)、肌酸磷酸激酶(CK),并进行比较。结果2组Scr、UAER水平均显著降低,但A组优于B组(P<0.05),2组的不良反应的发生率差异无统计学意义(P>0.05)。结论辛伐他汀治疗早期糖尿病肾病时,剂量与疗效呈正相关,而与不良反应的发生无明显相关性。
作者 刘俊伏 张刚 赵勇军
机构地区 河北省老年病医院内科
出处 《疑难病杂志》 CAS 2009年第9期544-545,共2页 Chinese Journal of Difficult and Complicated Cases
基金 河北省医学科学研究重点课题计划(No.08233)
关键词 辛伐他汀 糖尿病肾病 疗效 安全性
分类号 R587.2 [医药卫生—内分泌] R972.6 [医药卫生—内科学]
  • 相关文献

参考文献8

  • 1沈雅舟 吴松华 邵福源 等.糖尿病慢性并发症[M].上海：上海医科大学出版社,1999.207-234. 被引量：46
  • 2杨光伟,叶山东.他汀类药物对糖尿病肾病保护作用及其机制的研究进展[J].国外医学（老年医学分册）,2006,27(3):126-130. 被引量：8
  • 3Mogensen CE,Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria[ J ]. Lancet, 1995,346 (3 983 ) : 1 080-1 084. 被引量：1
  • 4Wolffenbuttel BHR, Franken AAM, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes : CORALL studay [ J ]. Intern Med, 2005,257 ( 6 ) :531-539. 被引量：1
  • 5Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats [ J ]. Nephrol Dial Transplant,2003,18 (2) :265-272. 被引量：1
  • 6Economides PA, Caselli A. Tiani E, et al. The effects of atorvastation on endothelial function in diabetic patients and subjects at risk for type 2 diabetes[J]. Clin Endocrinol Metab,2004,89 (2) :740-747. 被引量：1
  • 7Siddals KW, Marshman E, Westwood M, et al. Abrogation of insulin-like growth factor-Ⅰ( IGF-Ⅰ ) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways [J]. Biol Chem,2004,279(37) :38 353-38359. 被引量：1
  • 8Casey RG, Joyce M, Roche-Nagle G, et al. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease [J]. Surg Res,2005,123(2) :176-181. 被引量：1

二级参考文献19

  • 1American Diabetes Association. Management of dyslipidemia in adults with diabetes (Position Statement) . Diabetes Care, 19991 22 (suppl1): s56-s59. 被引量：1
  • 2Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet, 2003, 361 (9374): 2005-2016. 被引量：1
  • 3Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol,2001;21 (6): 449-454. 被引量：1
  • 4Wolffenbuttel BHR, Franken AAM, Vincent HH.Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetesCORALL study. J Intern Med, 2005; 257 (6): 531-539. 被引量：1
  • 5Massy ZA, Kim Y, Guijarro C et al. Low-density lipoprotein-induced expression of interleukin- 6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun, 2000;267 (2):536-540. 被引量：1
  • 6Ota T, Takamura T, Ando H et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia, 2003;46 (6): 843-851. 被引量：1
  • 7Siddals KW, Marshman E, Westwood M et al. Abrogation of insulin-like growth factor- Ⅰ(IGF-Ⅰ) and insulin action by mevalonic acid depletion:synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem, 2004; 279 (37): 38353- 38359. 被引量：1
  • 8Casey RG, Joyce M, Roche-Nagle G et al. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res, 2005;123 (2):176-181. 被引量：1
  • 9Kunieda Y, Nakagawa K, Nishimura H et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin Ⅱ in cultured rat aortic endothelial cells. Thromb Res, 2003;110 (4): 227-234. 被引量：1
  • 10Economides PA, Caselli A, Tiani E et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab, 2004;89 (2): 740-747. 被引量：1

共引文献52

同被引文献87

  • 1陆晔,郑杨,郭雁飞,李新建,程月华,何丽芸,徐继英,应韶旭,吴凡.上海市中老年人群中糖尿病发病与糖化血红蛋白基线值相关性的回顾性研究[J].实用老年医学,2013,27(1):35-37. 被引量：7
  • 2邱明才.糖尿病的多器官免疫损伤[J].国际内分泌代谢杂志,2006,26(3):215-216. 被引量：23
  • 3吴晓燕,汤旭磊,高林,陈莉,成建国.外周血Th1/Th2淋巴细胞失衡与2型糖尿病肾病的关系[J].兰州大学学报（医学版）,2007,33(1):30-33. 被引量：10
  • 4Usui H, Shikata K, Matsuda M, et al. HMG-CoA reduetase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant,2003,18 (2) :265-272. 被引量：1
  • 5Yokota N, O'DonneU M, Daniels F, et al. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrel,2003,23 ( 1 ) : 13-17. 被引量：1
  • 6Navarro JF, Mora C, Maca M, et al. Inflammatory parameters are in- dependently associated with urinary albumin in type 2 diabetes mel- litus. Am J Kidney Dis,2003,42( 1 ) :53-61. 被引量：1
  • 7Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA re- ductase inhibitors. Basic Res Cardiol,2002,97 (2) : 105-116. 被引量：1
  • 8Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin on plas- minogen activator inhibitor type-1 synthesis in human monoeytes/ macrophages. J Cardiovasc Pharmaco1,2001,37 (6) :762-768. 被引量：1
  • 9Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med,2008,359(21 ) :2195-2207. 被引量：1
  • 10Pickup JC. Inflammation and activated innate immunity in the pathogene- sis of type 2 diabetes [J]. Diabetes Care, 2004, 27 (3) : 813 - 823. 被引量：1

引证文献8

二级引证文献78

疑难病杂志
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部